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THE BATTLE THAT SEEMED LOST
Nanoparticles against multiresistant Pseudomonas aeruginosa
Paula Bellés Sancho 
EXPECTED RESULTS 
B I B L I O G R A P H Y
Pseudomonas aeruginosa is a gramnegative bacteria which causes most of the nosocomial
infections in humans. It is frequently associated with respiratory diseases, being the principal cause
of mortality(1). These infections are difficult to treat with antibiotics due to three main factors(2),
shown in the following figure (Figure 1):
The combination of these factors and the low bioavailability that, in most cases, traditional drugs
present, make the treatment ineffective. For this reason, new strategies based on nanocarriers
carrying antimicrobial drugs, such as polymeric nanoparticles (NPs), have been studied to due to
their potential to encapsulate and deliver the drug. These nanocarriers-based strategies are expected
to increase bactericidal effectiveness, avoiding the side effects reported on traditional drugs(2).
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Flowchart 1. Diagram of the specific objective. Each objective is considered as a work-package.  
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Figure 4. 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium (MTT) colorimetric assay
after 24 h and 48 h of exposure to different
NPsconcentrations, tested in murine macrophage
cells. Based on A. Baelo et al. 2015(4).
Figure 2. NPs preparation diagram based and modified from
Y. S. Nam et al. 2003(3) (1, 2 and 3) and A. Baelo et al. 2015(4)
(4). The NPs resulting is an amphiphilic NP based on PLGA-
PEI polymer and modified with Dnase I and CFZM.
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Figure 3. Flowchart on NPs characterization,
baseded and modified from A. Baelo et al.
2015(4) (1, 2, 3 and 4). Step 5 is based on M.
A. Vetten et al. 2014(5).
In vitro assays
Figure 5. In vitro assays
adapted from I. d’Angelo
et al. 2015(6) (1) and A.
Baelo et al. 2015(4) (2,
3.1. and 3.2.)
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Results of in vitro assays are represented
in Figure 6. Each expected result is related
to a component of the NPs, based on
previous studies(2, 4).
This project is designed for 3 years.
Results are expected to be obtained in the
last stage of the third year.
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Figure 1. Anatomical and biological barriers in respiratory infection diseases  
(Image modified from I. d’Angelo et al. 2014(2)).
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The aim of this project is:
To develop a polymeric NPs based on poly(lactic-co-glycolic) acid (PLGA) and
polyethylenimine (PEI). They will be modified by covalent grafting of
deoxyribonuclease I (DNase I) and will encapsulate ceftazidime (CFZM).
 To assess the NP bactericidal potential against P. aeruginosa infection with three
different in vitro assay (Flowchart 1).
